To include your compound in the COVID-19 Resource Center, submit it here.

Genset feels heat, lashes back

Genset S.A., which has been trying to execute the tricky move from the service space to the product space, last week found itself forced to stanch rumors that its fortunes were in peril in the wake of the abrupt departure of its vice president of physiological genomics.

Indeed, Bernard Bihain's departure last week to join ValiGen N.V. (Paris, France) as chief scientific officer drew a sharp public rebuke from Genset (NM:Genset; GENXY, Paris, France) in the wake of French newspaper reports about the scientist's exit.

Bihain was touted as the

Read the full 888 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE